skynesher / iStockphoto.com
Samsung and HP are just two technology companies that have diversified and invested in the life sciences industry. What impact will this type of activity have on the sector and will it be beneficial in the long run? LSIPR finds out.
When you think of big players in the life sciences sector, companies such as Gilead Sciences, Pfizer and AstraZeneca might spring to mind.
But the life sciences arena is changing, and companies that you might think better placed within the technology sector are making their presence felt in, and may be set to disrupt, the industry.
According to a report earlier this year by research and development insight company PatSnap, as of April 26, technology companies Philips and HP are among the top ten most intensive filers of patents covering enabling technologies in the synthetic biology field.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Samsung, HP, big data, patent filings, medical technology, research and development, consumer electronics, personalised medicine, life sciences, monitor
